Vedolizumab IV 300 mg in the Treatment of Fistulizing Crohn's Disease

NCT02630966 · clinicaltrials.gov ↗
PHASE4
Phase
COMPLETED
Status
34
Enrollment
INDUSTRY
Sponsor class

Conditions

Interventions

Sponsor

Takeda